# Kailera Therapeutics, Inc.: financial statements, quarterly

KLRA · Nasdaq · CIK 2096997 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/klra.md) · [Financials](/companies/klra/financials.md) · [Filings](/companies/klra/filings.md) · [Insiders](/companies/klra/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/klra/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Research and development | $m | [10.1](/filings/0001193125-26-239417.md) | [19.5](/filings/0001193125-26-346958.md) | [70.9](/filings/0001193125-26-239417.md) | [101](/filings/0001193125-26-346958.md) |
| Operating income | $m | [(20.5)](/filings/0001193125-26-239417.md) | [(30.7)](/filings/0001193125-26-346958.md) | [(84.7)](/filings/0001193125-26-239417.md) | [(121)](/filings/0001193125-26-346958.md) |
| Net income | $m | [(18.0)](/filings/0001193125-26-346958.md) | [(28.9)](/filings/0001193125-26-346958.md) | [(78.9)](/filings/0001193125-26-346958.md) | [(111)](/filings/0001193125-26-346958.md) |
| Diluted EPS | $ per share | [(17983.00)](/filings/0001193125-26-239417.md) | [(28947.00)](/filings/0001193125-26-346958.md) | [(3650.00)](/filings/0001193125-26-239417.md) | [(1.09)](/filings/0001193125-26-346958.md) |
| Basic EPS | $ per share | [(17983.00)](/filings/0001193125-26-239417.md) | [(28947.00)](/filings/0001193125-26-346958.md) | [(3650.00)](/filings/0001193125-26-239417.md) | [(1.09)](/filings/0001193125-26-346958.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | period not labelled (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [102](/filings/0001193125-26-239417.md) | [101](/filings/0001193125-26-346958.md) | [160](/filings/0001193125-26-346958.md) | [112](/filings/0001193125-26-239417.md) | [130](/filings/0001193125-26-346958.md) |
| Current assets | $m | not reported | not reported | not reported | [558](/filings/0001193125-26-346958.md) | [530](/filings/0001193125-26-239417.md) | [929](/filings/0001193125-26-346958.md) |
| Total assets | $m | not reported | not reported | not reported | [692](/filings/0001193125-26-346958.md) | [625](/filings/0001193125-26-239417.md) | [1,211](/filings/0001193125-26-346958.md) |
| Current liabilities | $m | not reported | not reported | not reported | [46.4](/filings/0001193125-26-346958.md) | [54.8](/filings/0001193125-26-239417.md) | [83.7](/filings/0001193125-26-346958.md) |
| Total liabilities | $m | not reported | not reported | not reported | [56.4](/filings/0001193125-26-346958.md) | [64.5](/filings/0001193125-26-239417.md) | [93.0](/filings/0001193125-26-346958.md) |
| Shareholders' equity | $m | [(219)](/filings/0001193125-26-346958.md) | [(235)](/filings/0001193125-26-346958.md) | [(263)](/filings/0001193125-26-346958.md) | [(356)](/filings/0001193125-26-346958.md) | [(432)](/filings/0001193125-26-346958.md) | [1,118](/filings/0001193125-26-346958.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(18.2)](/filings/0001193125-26-239417.md) | [(26.2) d](/filings/0001193125-26-346958.md) | [(68.3)](/filings/0001193125-26-239417.md) | [(77.5) d](/filings/0001193125-26-346958.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.0](/filings/0001193125-26-239417.md) | [0.0](/filings/0001193125-26-346958.md) | [0.0](/filings/0001193125-26-239417.md) | [102](/filings/0001193125-26-346958.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 129,643,676 at 2026-08-06, from the cover of the [10-Q filed 2026-08-12](/filings/0001193125-26-346958.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.